Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR4 | O00206 | 19/20 | 0.67 |
| ▸ | LY96 | Q9Y6Y9 | 4/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13325116 | 1.00 | TLR4 (0.67) | TLR4LY96 | |
| SCHEMBL13791345 | 1.00 | TLR4 (0.67) | TLR4LY96 | |
| SCHEMBL12762909 | 1.00 | TLR4 (0.67) | TLR4LY96 | |
| SCHEMBL13324193 | 1.00 | TLR4 (0.67) | TLR4LY96 | |
| SCHEMBL14071686 | 1.00 | TLR4 (0.67) | TLR4LY96 | |
| SCHEMBL13302912 | 1.00 | TLR4 (0.67) | TLR4LY96 | |
| SCHEMBL10071015 | 1.00 | TLR4 (0.67) | TLR4LY96 | |
| SCHEMBL10042139 | 1.00 | TLR4 (0.67) | TLR4LY96 | |
| SCHEMBL13804057 | 1.00 | TLR4 (0.67) | TLR4LY96 | |
| SCHEMBL13791998 | 0.96 | TLR4 (0.62) | TLR4LY96 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399634-B2 | Reagents and methods for preparing LPS antagonist B1287 and stereoisomers thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-03-19 | — | — | US | disclosed |
| US-8207144-B2 | Improves the stability over time of a corresponding tetrasodium salt useful as a preventive or therapeutic for septicemia, endotoxemia or improving prognosis following coronary artery bypass surgery | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2012-06-26 | — | — | US | disclosed |
| US-8207144-B2 | Improves the stability over time of a corresponding tetrasodium salt useful as a preventive or therapeutic for septicemia, endotoxemia or improving prognosis following coronary artery bypass surgery | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2012-06-26 | — | — | US | disclosed |
| US-20110152508-A1 | REAGENTS AND METHODS FOR PREPARING LPS ANTAGONIST B1287 AND STEREOISOMERS THEREOF | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-06-23 | — | — | US | disclosed |
| US-7906633-B2 | Reagents and methods for preparing LPS antagonist B1287 and stereoisomers thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-03-15 | — | — | US | disclosed |
| US-20100152429-A1 | SODIUM SALT OF DISACCHARIDE COMPOUND, METHOD FOR PRODUCING THE SAME, AND USE OF THE SAME | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-06-17 | — | — | US | disclosed |
| US-20100152429-A1 | SODIUM SALT OF DISACCHARIDE COMPOUND, METHOD FOR PRODUCING THE SAME, AND USE OF THE SAME | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-06-17 | — | — | US | disclosed |
| US-20090149647-A1 | PROCESS FOR PRODUCTION OF LIPID A ANALOGUE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149647-A1 | PROCESS FOR PRODUCTION OF LIPID A ANALOGUE | DDOST, PHOSPHO1, DCPS | TLR4 2691/4885LY96 3397/4885 |
| US-20100152429-A1 | SODIUM SALT OF DISACCHARIDE COMPOUND, METHOD FOR PRODUCING THE SAME, AND USE OF THE SAME | MAN2B2, MAN2A1, MAN2B1 | TLR4 1500/4885LY96 4612/4885 |
| US-20110152508-A1 | REAGENTS AND METHODS FOR PREPARING LPS ANTAGONIST B1287 AND STEREOISOMERS THEREOF | LTB4R2, LTB4R, LITAF | TLR4 24/4885LY96 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.